{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:40:24Z","timestamp":1778168424916,"version":"3.51.4"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015378","name":"Shanghai University of Medicine and Health Sciences","doi-asserted-by":"publisher","award":["A1-0200-24-201008-13"],"award-info":[{"award-number":["A1-0200-24-201008-13"]}],"id":[{"id":"10.13039\/501100015378","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2411205"],"award-info":[{"award-number":["2023YFC2411205"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005153","name":"National Science Fund for Distinguished Young Scholars","doi-asserted-by":"publisher","award":["81802583"],"award-info":[{"award-number":["81802583"]}],"id":[{"id":"10.13039\/501100005153","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Genetics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.cancergen.2024.12.005","type":"journal-article","created":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T06:47:12Z","timestamp":1735454832000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Prognosis prediction and drug guidance of ovarian serous cystadenocarcinoma through mitochondria gene-based model"],"prefix":"10.1016","volume":"292-293","author":[{"given":"Dongsheng","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenghao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaifang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowen","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenghu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergen.2024.12.005_bib0001","first-page":"561","article-title":"Ovarian cancer: an overview","volume":"91","author":"Penny","year":"2020","journal-title":"Radiol Technol"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0002","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0003","first-page":"68","article-title":"Cancer statistics, 2018","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","article-title":"Cancer treatments: Past, present, and future","volume":"286-287","author":"Sonkin","year":"2024","journal-title":"Cancer Genetics"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021224","article-title":"Ovarian cancer: a landscape of mitochondria with emphasis on mitochondrial dynamics","volume":"24","author":"De Rasmo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0008","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091350","article-title":"Human ovarian cancer tissue exhibits increase of mitochondrial biogenesis and cristae remodeling","volume":"11","author":"Signorile","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0009","doi-asserted-by":"crossref","first-page":"e11487","DOI":"10.1016\/j.heliyon.2022.e11487","article-title":"Recent advances in understanding the metabolic plasticity of ovarian cancer: A systematic review","volume":"8","author":"Kobayashi","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0010","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/cr.2009.69","article-title":"Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis","volume":"19","author":"Lu","year":"2009","journal-title":"Cell Res"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0011","article-title":"Mitochondrial dysfunction route as a possible biomarker and therapy target for human cancer","author":"Al-Faze","year":"2024","journal-title":"Biomed J"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0012","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.7150\/thno.70194","article-title":"SCD1\/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells","volume":"12","author":"Xuan","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0013","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12929-023-00956-w","article-title":"Role of mitochondrial alterations in human cancer progression and cancer immunity","volume":"30","author":"Wang","year":"2023","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0014","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1186\/s12967-024-05770-y","article-title":"Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer","volume":"22","author":"Cui","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114551","article-title":"Carcinoma-associated mesenchymal stem cells promote ovarian cancer heterogeneity and metastasis through mitochondrial transfer","volume":"43","author":"Frisbie","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0016","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s12276-023-01011-2","article-title":"Metastatic pattern of ovarian cancer delineated by tracing the evolution of mitochondrial DNA mutations","volume":"55","author":"Xu","year":"2023","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0017","doi-asserted-by":"crossref","first-page":"217","DOI":"10.6004\/jnccn.2022.7254","article-title":"Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer","volume":"21","author":"Gordhandas","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0018","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","article-title":"Uterine Neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0019","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0020","first-page":"107","article-title":"Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer","author":"Ramus","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0021","article-title":"Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer","volume":"14","author":"Huang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0022","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13046-022-02265-w","article-title":"Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients","volume":"41","author":"Buttarelli","year":"2022","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0023","doi-asserted-by":"crossref","first-page":"g7594","DOI":"10.1136\/bmj.g7594","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"350","author":"Collins","year":"2015","journal-title":"Bmj"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0024","doi-asserted-by":"crossref","first-page":"D1541","DOI":"10.1093\/nar\/gkaa1011","article-title":"MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations","volume":"49","author":"Rath","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0025","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.18632\/oncotarget.13643","article-title":"Novel Src\/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src\/ Abl signaling","volume":"8","author":"Bieerkehazhi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0026","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.18632\/oncotarget.13657","article-title":"Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma","volume":"8","author":"Mao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0027","first-page":"15","article-title":"Aptamer-Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells","author":"Qi","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0028","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/j.ymthe.2022.02.004","article-title":"Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer","volume":"30","author":"Wan","year":"2022","journal-title":"Mol Therapy"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0029","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.18632\/oncotarget.11580","article-title":"Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0030","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0031","first-page":"10","article-title":"Oxidative phosphorylation: a target for novel therapeutic strategies against ovarian cancer","author":"Nayak","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0032","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7150\/ijbs.81609","article-title":"An overview: the diversified role of mitochondria in cancer metabolism","volume":"19","author":"Liu","year":"2023","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216057","article-title":"Molecular characteristics and clinical behaviour of epithelial ovarian cancers","volume":"555","author":"Hollis","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0034","first-page":"2674","article-title":"Regulatory mechanism of fatty acid\u2011CoA metabolic enzymes under endoplasmic reticulum stress in lung cancer","volume":"40","author":"Liu","year":"2018","journal-title":"Oncol Rep"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0035","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.62347\/OIQB4997","article-title":"Low expression of ACOT13 predicts poor prognosis and immunotherapy outcome in ovarian cancer","volume":"16","author":"Xie","year":"2024","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1213022","article-title":"Low expression of acyl-CoA thioesterase 13 is associated with poor prognosis in ovarian serous cystadenocarcinoma","volume":"14","author":"Lv","year":"2023","journal-title":"Front Genet"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0037","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/cam4.1295","article-title":"Mitochondrial Acetyl-CoA synthetase 3 is biosignature of gastric cancer progression","volume":"7","author":"Chang","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0038","doi-asserted-by":"crossref","first-page":"E11874","DOI":"10.1073\/pnas.1807305115","article-title":"Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes","volume":"115","author":"Bidkhori","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0039","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cmet.2015.04.012","article-title":"Cooperation between COA6 and SCO2 in COX2 maturation during cytochrome c oxidase assembly links two mitochondrial cardiomyopathies","volume":"21","author":"Pacheu-Grau","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.11.054","article-title":"COA6 is structurally tuned to function as a thiol-disulfide oxidoreductase in copper delivery to mitochondrial cytochrome c oxidase","volume":"29","author":"Soma","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0041","article-title":"High Expression of COA6 is related to unfavorable prognosis and enhanced oxidative phosphorylation in lung adenocarcinoma","volume":"24","author":"Zhang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0042","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202201413","article-title":"FKBP4 regulates 5-fluorouracil sensitivity in colon cancer by controlling mitochondrial respiration","volume":"5","author":"Zhu","year":"2022","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0043","article-title":"The expression of cuproptosis-related genes in hepatocellular carcinoma and their relationships with prognosis","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0044","doi-asserted-by":"crossref","first-page":"13521","DOI":"10.18632\/oncotarget.14587","article-title":"HINT2 downregulation promotes colorectal carcinoma migration and metastasis","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0045","doi-asserted-by":"crossref","first-page":"R215","DOI":"10.1186\/gb-2007-8-10-r215","article-title":"High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer","volume":"8","author":"Chin","year":"2007","journal-title":"Genome Biol"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0046","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/s42255-021-00481-w","article-title":"Sex-specific genetic regulation of adipose mitochondria and metabolic syndrome by Ndufv2","volume":"3","author":"Chella Krishnan","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0047","article-title":"Identifying Mitochondrial-Related Genes NDUFA10 and NDUFV2 as Prognostic Markers for Prostate Cancer through Biclustering","volume":"2021","author":"Zhang","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0048","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/1871520618666180816142821","article-title":"Modulation of mitochondrial and epigenetic targets by polyphenols-rich extract from araucaria angustifolia in larynx carcinoma","volume":"19","author":"Branco","year":"2019","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0049","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/mc.23381","article-title":"The FoxQ1 transcription factor is a novel regulator of electron transport chain complex I subunits in human breast cancer cells","volume":"61","author":"Kim","year":"2022","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0050","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/15548627.2021.1964224","article-title":"LC3A-mediated autophagy regulates lung cancer cell plasticity","volume":"18","author":"Miao","year":"2022","journal-title":"Autophagy"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0051","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13048-023-01326-8","article-title":"Development and clinical validation of a seven-gene signature based on tumor stem cell-related genes to predict ovarian cancer prognosis","volume":"17","author":"Wang","year":"2024","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0052","article-title":"Ferroptosis-related long noncoding rnas as prognostic biomarkers for ovarian cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0053","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13048-023-01142-0","article-title":"A novel DNA methylation-related gene signature for the prediction of overall survival and immune characteristics of ovarian cancer patients","volume":"16","author":"Wang","year":"2023","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0054","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1458264","article-title":"Explore the expression of mitochondria-related genes to construct prognostic risk model for ovarian cancer and validate it, so as to provide optimized treatment for ovarian cancer","volume":"15","author":"Yunyun","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0055","doi-asserted-by":"crossref","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","article-title":"NCCN Guidelines\u00ae Insights: Ovarian Cancer, Version 3.2022","volume":"20","author":"Armstrong","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0056","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review","author":"Richardson","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0057","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246246","article-title":"Mechanisms of drug resistance in ovarian cancer and associated gene targets","volume":"14","author":"Alatise","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0058","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejca.2022.11.029","article-title":"Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged \u226565 years from the PAOLA-1\/ENGOT-ov25 trial","volume":"181","author":"Sabatier","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0059","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","article-title":"Anti-angiogenic agents in ovarian cancer: past, present, and future","volume":"27 Suppl 1","author":"Monk","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0060","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(22)00196-6","article-title":"Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial","volume":"23","author":"Saji","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0061","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.5990","article-title":"A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma","author":"Ness","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0062","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/bju.15165","article-title":"Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)","volume":"126","author":"Rodriguez-Vida","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0063","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.27782","article-title":"BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer","volume":"119","author":"Grisham","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0064","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2023.03.019","article-title":"Survival in melanoma in the nordic countries into the era of targeted and immunological therapies","volume":"186","author":"Tichanek","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0065","doi-asserted-by":"crossref","first-page":"11100","DOI":"10.1158\/0008-5472.CAN-06-2554","article-title":"Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885","volume":"66","author":"King","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0066","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","article-title":"Homologous recombination deficiencies, and synthetic lethality","volume":"83","author":"Murai","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0067","doi-asserted-by":"crossref","DOI":"10.1080\/01443615.2023.2171282","article-title":"Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis","volume":"43","author":"Li","year":"2023","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121259","article-title":"Targeted immunotherapy of triple-negative breast cancer by aptamer-engineered NK cells","volume":"280","author":"Chen","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1111061","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100502","article-title":"Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma","volume":"22","author":"Kim","year":"2023","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0071","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133343","article-title":"Identification of a novel tumor microenvironment prognostic signature for advanced-stage serous ovarian cancer","volume":"13","author":"Zheng","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cancergen.2024.12.005_bib0072","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.677697","article-title":"Single-Cell RNA-sequencing portraying functional diversity and clinical implications of IFI6 in ovarian cancer","volume":"9","author":"Zhao","year":"2021","journal-title":"Front Cell Dev Biol"}],"container-title":["Cancer Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776224001583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776224001583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T06:52:46Z","timestamp":1741589566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210776224001583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":72,"alternative-id":["S2210776224001583"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergen.2024.12.005","relation":{},"ISSN":["2210-7762"],"issn-type":[{"value":"2210-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognosis prediction and drug guidance of ovarian serous cystadenocarcinoma through mitochondria gene-based model","name":"articletitle","label":"Article Title"},{"value":"Cancer Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cancergen.2024.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}